K Cherry Liu1, Mansour Farahani, Tshililo Mashamba, Muthuhadini Mawela, Jessica Joseph, Nienke Van Schaik, Engela Honey, Michelle Gill, Waasila Jassat, Elizabeth M Stringer, Namiwnga Chintu, Richard G Marlink. 1. aCentre for Infectious Disease Research in Zambia, Lusaka, Zambia bUniversity of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina cHarvard University School of Public Health, Boston, Massachusetts, USA dUniversity of Limpopo Medical University of Southern Africa, Pretoria eHealth Systems Trust, Durban fUniversity of Pretoria, Pretoria, South Africa gElizabeth Glaser Pediatric AIDS Foundation hGeorge Washington University School of Public Health and Health Services, Washington, District of Columbia, USA.
Abstract
OBJECTIVE: To evaluate the safety of combination antiretroviral therapy (ART) in conception and pregnancy in different health systems. DESIGN: A pilot ART registry to measure the prevalence of birth defects and adverse pregnancy outcomes in South Africa and Zambia. METHODS: HIV-infected pregnant women on ART prior to conception were enrolled until delivery, and their infants were followed until 1 year old. RESULTS: Between October 2010 and April 2011, 600 women were enrolled. The median CD4 cell count at study enrollment was lower in South Africa than Zambia (320 vs. 430 cells/μl; P < 0.01). The most common antiretroviral drugs at the time of conception included stavudine, lamivudine, and nevirapine. There were 16 abortions (2.7%), one ectopic pregnancy (0.2%), 12 (2.0%) stillbirths, and 571 (95.2%) live infants. Deliveries were more often preterm (29.7 vs. 18.4%; P = 0.01) and the infants had lower birth weights (2900 vs. 2995 g; P = 0.11) in Zambia compared to South Africa. Thirty-six infants had birth defects: 13 major and 23 minor. There were more major anomalies detected in South Africa and more minor ones in Zambia. No neonatal deaths were attributed to congenital birth defects. CONCLUSIONS: An Africa-specific, multi-site antiretroviral drug safety registry for pregnant women is feasible. Different prevalence for preterm delivery, delivery mode, and birth defect types between women on preconception ART in South Africa and Zambia highlight the potential impact of health systems on pregnancy outcomes. As countries establish ART drug safety registries, documenting health facility limitations may be as essential as the specific ART details.
OBJECTIVE: To evaluate the safety of combination antiretroviral therapy (ART) in conception and pregnancy in different health systems. DESIGN: A pilot ART registry to measure the prevalence of birth defects and adverse pregnancy outcomes in South Africa and Zambia. METHODS:HIV-infected pregnant women on ART prior to conception were enrolled until delivery, and their infants were followed until 1 year old. RESULTS: Between October 2010 and April 2011, 600 women were enrolled. The median CD4 cell count at study enrollment was lower in South Africa than Zambia (320 vs. 430 cells/μl; P < 0.01). The most common antiretroviral drugs at the time of conception included stavudine, lamivudine, and nevirapine. There were 16 abortions (2.7%), one ectopic pregnancy (0.2%), 12 (2.0%) stillbirths, and 571 (95.2%) live infants. Deliveries were more often preterm (29.7 vs. 18.4%; P = 0.01) and the infants had lower birth weights (2900 vs. 2995 g; P = 0.11) in Zambia compared to South Africa. Thirty-six infants had birth defects: 13 major and 23 minor. There were more major anomalies detected in South Africa and more minor ones in Zambia. No neonatal deaths were attributed to congenital birth defects. CONCLUSIONS: An Africa-specific, multi-site antiretroviral drug safety registry for pregnant women is feasible. Different prevalence for preterm delivery, delivery mode, and birth defect types between women on preconception ART in South Africa and Zambia highlight the potential impact of health systems on pregnancy outcomes. As countries establish ART drug safety registries, documenting health facility limitations may be as essential as the specific ART details.
Authors: Muktar H Aliyu; O'Neil Lynch; Victoria Belogolovkin; Roger Zoorob; Hamisu M Salihu Journal: Eur J Public Health Date: 2010-04-07 Impact factor: 3.367
Authors: Jennifer Y Chen; Heather J Ribaudo; Sajini Souda; Natasha Parekh; Anthony Ogwu; Shahin Lockman; Kathleen Powis; Scott Dryden-Peterson; Tracy Creek; William Jimbo; Tebogo Madidimalo; Joseph Makhema; Max Essex; Roger L Shapiro Journal: J Infect Dis Date: 2012-10-12 Impact factor: 5.226
Authors: Hermann Bussmann; C William Wester; Carolyn N Wester; Bright Lekoko; Okechukwu Okezie; Ann Muir Thomas; S M Victor DeGruttola; Joseph Makhema; Max Essex; Richard G Marlink Journal: J Acquir Immune Defic Syndr Date: 2007-07-01 Impact factor: 3.731
Authors: Risa M Hoffman; Sean S Brummel; Paula Britto; Jose H Pilotto; Gaerolwe Masheto; Linda Aurpibul; Esau Joao; Murli U Purswani; Shelley Buschur; Marie Flore Pierre; Anne Coletti; Nahida Chakhtoura; Karin L Klingman; Judith S Currier Journal: Clin Infect Dis Date: 2019-01-07 Impact factor: 9.079
Authors: Ushma C Mehta; Cari van Schalkwyk; Prineetha Naidoo; Arthi Ramkissoon; Otty Mhlongo; Niren R Maharaj; Niree Naidoo; Karen Fieggen; Michael F Urban; Shaun Krog; Alex Welte; Mukesh Dheda; Yogan Pillay; Neil F Moran Journal: South Afr J HIV Med Date: 2019-09-30 Impact factor: 2.744
Authors: Armel Poda; Arsène Hema; Aina Konaté; Firmin Kaboré; Jacques Zoungrana; Euloges Kamboulé; Ibrahim Soré; Guillaume Bado; Abdoul-Salam Ouédraogo; Macaire Ouédraogo; Nicolas Meda; Adrien Bruno Sawadogo Journal: Pan Afr Med J Date: 2016-03-16